Novartis first-in-class Cosentyx approved in China for psoriasis patients
- China Health Authority NMPA approved Cosentyx??(secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
- Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)[1]-[2]?
- A Phase III study in patients in China with psoriasis confirmed a sustained safety profile and rapid onset of relief with Cosentyx as early as week 3. Data showed close to 9/10 patients who received Cosentyx??(300mg on an every 4 week dosing regimen after loading) achieved clear or almost clear skin after 16 weeks[3]
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail:?media.relations@novartis.com- Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com
- Friedrich von Heyl Novartis Global Pharma Communications +41 61 324 8984 (direct) +41 79 749 0286 (mobile) friedrich.vonheyl@novartis.com